ProfileGDS5678 / 1459554_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 52% 46% 46% 45% 45% 50% 56% 46% 45% 46% 46% 46% 49% 46% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.3023152
GSM967853U87-EV human glioblastoma xenograft - Control 23.0892546
GSM967854U87-EV human glioblastoma xenograft - Control 33.094146
GSM967855U87-EV human glioblastoma xenograft - Control 42.985345
GSM967856U87-EV human glioblastoma xenograft - Control 53.0117845
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.2897850
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.5044456
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.0823446
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.0320545
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.0560146
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.073946
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.0531146
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.1647349
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.0815246